HACARUS Brings Sparse Modeling to Drug Discovery with Mitsubishi Tanabe Pharma

HACARUS, the provider of big insights from small data, today announced the strong results of joint research with Mitsubishi Tanabe Pharma Corporation related to the screening process, focused on first-in-class drug discovery.

Dr. Akihiko Taguchi of FBRI's research was published in the electronic version of the American scientific journal "Stem Cells"

Akihiko Taguchi et al., Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation, FBRI, have elucidated the mechanism of cerebral neuronal function regenerative and hyperinflammation control by stem cell therapy using mesenchymal stem cells.

Prof. Minako Hoshi of FBRI's research on Alzheimer's disease was published in the British Journal of Pharmacology (BJP)

Dr. Hoshi, Professor of the Department for Brain and Neurodegenerative Disease Research, FBRI and colleagues have prove that a unique toxic structure termed amyl spheroid inhibits the action of the neuron-specific sodium pump, which is essential for neuronal activity, and causes neuronal death, leading to Alzheimer's disease.

Meiji Seika Pharma Co., Ltd. and the FBRI successfully created an antibody drug candidate for the treatment of autoimmune disease through collaborative research

Meiji Seika Pharma Co., Ltd. and the FBRI were aiming to develop a revolutionary pharmaceutical as the first collaborative research program of the Kobe Biomedical Innovation Cluster. From April 2016, they performed collaborative research for five years to discover drugs for autoimmune diseases and cancer in the first "Drug Discovery Innovation Program" administered and managed by the foundation.